XTANDI™▼ (Enzalutamide) Authorised in the European Union (EU) for Advanced Prostate Cancer

  XTANDI™▼ (Enzalutamide) Authorised in the European Union (EU) for Advanced
  Prostate Cancer

Enzalutamide authorised in European Union (EU) for the treatment of adult men
    with metastatic castration-resistant prostate cancer whose disease has
                  progressed on or after docetaxel therapy^1

Business Wire

CHERTSEY, ENGLAND & SAN FRANCISCO, CA -- June 24, 2013

Today, Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based
Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq: MDVN), announce
that following the regulatory review process by the European Medicines Agency
(EMA) and a positive Committee for Medicinal Products for Human Use (CHMP)
opinion on 25^th April 2013,^2 the European Commission (EC) has granted the
marketing authorisation for XTANDI (enzalutamide) capsules for the treatment
of adult men with metastatic castration-resistant prostate cancer whose
disease has progressed on or after docetaxel therapy.^1

Enzalutamide is a novel, once-daily, oral androgen receptor signalling
inhibitor.^3 It inhibits multiple steps in the androgen receptor (AR)
signalling pathway, which has been shown to decrease cancer cell growth and
induce cancer cell death (apoptosis).^3

Professor Johann de Bono, Professor of Experimental Cancer Medicine at The
Institute of Cancer Research, London, and Consultant Medical Oncologist at The
Royal Marsden NHS Foundation Trust, said: “This is a major development in
prostate cancer therapeutics that will provide an important new treatment
option for patients with advanced prostate cancer following chemotherapy.”

Professor de Bono, who is also Head of the Drug Development Unit, a joint
facility between The Royal Marsden NHS Foundation Trust and The Institute of
Cancer Research, located at The Royal Marsden, added: “Enzalutamide, an oral
drug, improves the quality of life and survival time for patients who have an
advanced form of this common disease and is generally well tolerated.”

The EU authorisation is based on results from the phase III AFFIRM study which
confirmed that enzalutamide demonstrated a statistically significant
improvement (p<0.0001) in overall survival compared to placebo, with a median
survival of 18.4 months in the enzalutamide group versus 13.6 months in the
placebo group, an advantage of 4.8 months [hazard ratio (HR) = 0.631]. The
study also concluded that enzalutamide was generally well tolerated by
patients and met all secondary endpoints.^4 The phase III AFFIRM trial was a
randomised, double-blind, placebo-controlled, multinational trial evaluating
enzalutamide (160 mg/day) versus placebo in 1,199 men with progressive
metastatic castration-resistant prostate cancer who were previously treated
with docetaxel-based chemotherapy.^4

Advanced prostate cancer is defined as cancer that has spread outside of the
prostate to other areas of the body (metastasised).^4 A high number of men
with advanced prostate cancer eventually develop resistance to androgen
deprivation treatment, which is called castration-resistant prostate cancer
(CRPC).^5 Around 10-20% of patients with prostate cancer present at an
advanced stage, and up to 40% of men diagnosed with prostate cancer will
eventually develop advanced disease.^6,7

Dr Erik Briers, Executive Director, European Cancer Patient Coalition (ECPC)
and member of the strategic committee of Europa Uomocomments:“Unfortunately
prostate cancer can evolve into a life threatening castration resistant
metastatic condition where treatment options are needed because all patients
are not identical. A new treatment such as enzalutamide is one more option
that will give selected patients a new chance if other options fail. Patients
with advanced prostate cancer are very concerned about their quality of life,
so they favour treatments with fewer side effects. Enzalutamide has been shown
to be generally well tolerated.”

Upon receiving marketing authorisation in Europe, Astellas will provide
Medivation with a $15 million milestone payment, as reflected in Astellas’
current fiscal year (from 1^st April 2013 to 31^st March 2014) financial
forecast.

Enzalutamide was licensed by the U.S. Food and Drug Administration on 31^st
August, 2012 and launched in the U.S. in September 2012 for the treatment of
patients with metastatic castration-resistant prostate cancer (mCRPC) who have
previously received docetaxel (chemotherapy).^8

The EC grant of the marketing authorisation applies in all European Union (EU)
Member States, as well as in the European Economic Area (EEA) countries
Iceland, Liechtenstein and Norway.

  *Ends -

Notes to Editors:

About Prostate Cancer

Prostate cancer is the most frequently diagnosed cancer among European men and
it is becoming more common. ^6,9

Patients with metastatic CRPC currently have few treatment options. There is
an unmet need in this area for new compounds that target the cancer
differently and which may provide alternative therapeutic options for patients
at this late stage of their disease.^7

About Enzalutamide

Enzalutamide is a novel, oral, once-daily androgen receptor signalling
inhibitor.^3,4

Enzalutamide inhibits androgen receptor signalling in three distinct ways: it
inhibits 1) testosterone binding to androgen receptors; 2) nuclear
translocation of androgen receptors; and 3) DNA binding and activation by
androgen receptors.^3,4

About AFFIRM

The phase III AFFIRM trial is a randomised, double-blind, placebo-controlled,
multinational trial evaluating enzalutamide (160 mg/day) versus placebo in
1,199 men with progressive metastatic castration-resistant prostate cancer who
were previously treated with docetaxel-based chemotherapy. Enrolment was
completed in November 2010 and the interim analysis was triggered at 520
events. The median age of study participants was 69 years at baseline.^4

The AFFIRM study was conducted at sites in the United States, Canada, Europe,
Australia, South America and South Africa.^4

The primary endpoint of the AFFIRM trial was overall survival. Key secondary
endpoints included time to prostate-specific antigen (PSA) progression,
radiographic progression free survival (rPFS) and time to first
skeletal-related event (SRE).^4

In the phase III AFFIRM trial, enzalutamide was generally well tolerated.^4
The most common adverse reactions were hot flushes and headache.^10 Seizure
was reported in 0.8% of enzalutamide-treated patients.^10 Serious adverse
events, adverse events causing patients to stop treatment, and adverse events
causing death were all lower in the enzalutamide group than in the placebo
group.^4

About Astellas Pharma Europe

Astellas Pharma Europe Ltd., located in the UK, is the European Headquarters
of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceuticals. As a global company,
Astellas is committed to combining outstanding research and development (R&D)
and marketing capabilities to continue to grow in the world pharmaceutical
market. Astellas Pharma Europe Ltd. manages 21 affiliate offices located
across Europe, the Middle East and Africa. In addition, the Company has an R&D
site and three manufacturing plants in Europe. The company employs over 4,300
staff across these regions. For more information about Astellas Pharma Europe,
please visit http://www.astellas.eu.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which there are
limited treatment options. Medivation aims to transform the treatment of these
diseases and offer hope to critically ill patients and their families. For
more information, please visit us at www.medivation.com.

About the Medivation/Astellas Collaboration

In October 2009, Medivation and Astellas entered into a global agreement to
jointly develop and commercialise enzalutamide (formerly MDV3100).The
companies are collaborating on a comprehensive development programme that
includes studies to develop enzalutamide across the full spectrum of advanced
prostate cancer. The companies are jointly commercialising enzalutamide in the
United States and Astellas will have responsibility for commercialising
enzalutamide outside the U.S, pending further regulatory authorisation. To
date, enzalutamide has been filed in Japan, Switzerland and Brazil, and has
received authorisation in the US, Canada and the EU.

                                     ###

References

1. European Commission. Adoption of COMMISSION IMPLEMENTING DECISION granting
marketing authorisation under Regulation (EC) No 726/2004 of the European
Parliament and of the Council for "Xtandi - enzalutamide", a medicinal product
for human use. Letter dated 21.06.13.

2. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion
(initial authorisation). Xtandi. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002639/WC500142493.pdf
(Last accessed June 2013)

3. Scher H I, et al. Antitumour activity of MDV3100 in castration-resistant
prostate cancer: a phase 1–2 study. The Lancet 2010;375(9724):1437-46

4. Scher H I, et al. MDV3100, an Androgen Receptor Signaling Inhibitor (ARSI),
Improves Overall Survival in Patients With Prostate Cancer Post Docetaxel;
Results From the Phase 3 Affirm Study. Presented at ASCO-GU, 02 February 2012

5. Macmillan Cancer Support, Hormonal therapy for advanced prostate cancer.
Available at:
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Treatmentforadvancedprostatecancer/Hormonaltherapy.aspx
(Last accessed June 2013)

6. Beltran H. et al, Collaborative Review – Prostate Cancer New Therapies for
Castration-Resistant Prostate Cancer: Efficacy and Safety, European Urology
2011; 60(2):279-290

7. Yap T A, et al. The changing therapeutic landscape of castration-resistant
prostate cancer, Nat. Rev. Clin. Oncol 2011;8(10):597-610

8. FDA. Enzalutamide (XTANDI Capsules). Available from:
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm317997.htm (Last
accessed June 2013)

9. Globocan 2008. WHO Europe Region (EURO); Prostate cancer incidence,
mortality and prevalence worldwide in 2008European Union (EU-27): estimated
incidence, mortality and 5-year prevalence: men.
http://globocan.iarc.fr/factsheet.asp (Last accessed June 2013)

10. SMPC. Astellas Pharma Europe Ltd. Data on file

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130623005061/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50657796&lang=en

Contact:

Claire Nicholson
Red Health
claire.nicholson@redconsultancy.com
Tel: +44 207 025 6524
or
Mindy Dooa
Communications Director
Astellas Pharma Europe Ltd.
Mindy.Dooa@astellas.com
 
Press spacebar to pause and continue. Press esc to stop.